ABSTRACT
INTRODUCTION
Diabetes is one of the most common chronic diseases and a growing global epidemic (Danaei et al., 2011) .
1 Type 2 diabetes (T2D) is a serious metabolic disease characterised by high glucose levels. Complications from T2D usually result in poor quality of life, disability, and early death. 2 Despite efforts to control glycaemia in diabetes patients, no therapeutic approach has significantly impacted the progression of this disease (Tahrani et al., 2010) . 3 There is, however, a simple and reversible surgical procedure that might become a valid therapeutic alternative in non-obese patients. This procedure, isolated ileal interposition (III), results in a dramatic increase in the incretin glucagon-like peptide 1 (GLP-1).
Epidemiology and aetiopathogenesis of diabetes
In 2000, diabetes caused the death of about three million people. 4 In 2010, the number of affected individuals was approximately 285 million, and this number is projected to increase 54% by 2030. A much greater increase in the number of adults with diabetes is projected in underdeveloped countries than in developed countries: the number of affected individuals is projected to increase approximately 70% in underdeveloped countries and 20% in developed countries. 1 T2D, also known as non-insulin-dependent diabetes, is responsible for 90% to 95% of diabetes cases.
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T2D is a progressive heterogeneous disease that mainly involves peripheral insulin resistance and gradual dysfunction of pancreatic beta cells. 2, 6 It develops when pancreatic islets can no longer maintain insulinaemia at levels sufficient to overcome peripheral tissue resistance. Throughout the course of the disease, diabetes passes through intermediate stages. Initially, diabetes is treated only with modifications in lifestyle and specific diet. Later in the disease, patients are treated with drugs that promote insulin secretion. As insulin deficiency unavoidably increases, however, the combination of therapeutic oral agents often fails to control hyperglycaemia efficiently, and the use of insulin is eventually required. [6] [7] [8] [9] In the long run, patients with T2D have an increased risk of complications that are a substantial cause of morbidity and mortality, including macrovascular disease, nephropathy, retinopathy, and neuropathy. 10 Further complications of diabetes include ischemia of the limbs resulting in amputation, dental problems, and pregnancy disorders. 5 The risk of developing diabetes-associated complications is related to the duration of diabetes and the level of glycaemic control.
Although 90% of T2D cases can be attributed to excessive weight, 12 its incidence is growing among individuals with body mass index (BMI) in the normal and overweight ranges.
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Treatment of diabetes
T2D is a multifaceted condition requiring an integrated and individualised approach to each patient's care that can prove quite challenging (Freeman, 2010) . 15 Treatment must initially be based on substantial lifestyle changes, including diet adjustment and regular physical activity. In most patients, these behavioural measures eventually do not suffice to keep glycaemia within appropriate levels, and oral antidiabetic agents are added. 17 Currently, there are several drug classes with different mechanisms of action that might be used singly or in various therapeutic combinations. 16 Many patients eventually require combinations of two or more oral drugs. [17] [18] [19] Despite these treatments, glycaemia increases over time as the disease progresses, requiring the use of insulin in combination with oral agents and eventual full insulinisation. Although these interventions might decrease peripheral blood glycaemia, none of these actions is effective in stopping disease progression. 9 Intensification of insulin therapy is the most appropriate intervention used to attempt to achieve normoglycaemia and reduce complications through early, strict, persistent, and effective control of glycaemia. 16, 20, 21 Thus, insulin is currently the only effective conservative therapeutic option for achieving metabolic control. 6, 7, 22 However, the use of external insulin is not easy to manage. Attaining optimal glicemic levels, i.e., glycaemia levels as close as possible to those of a non-diabetic individual 23 in order to prevent complications, still poses a major challenge in clinical practice. 2, 21 Due to the limitations of most of the available therapeutic measures, only a small fraction of the diabetic population meets therapeutic goals. 23 These limitations include poor compliance with diets, resistance to physical exercise programmes, limited efficacy and significant side effects of current therapeutic agents, delays in insulin therapy onset, and patient aversion to the multiple parenteral injection regimes required for the administration of insulin. [21] [22] [23] [24] Successful insulin therapy requires accurate information, motivation, high socioeconomic and cultural levels, high adherence and learning ability, availability of resources, and participation of and support by a multiprofessional team.
Some antidiabetic drugs accelerate beta cell apoptosis, 2 whereas others reduce bone mineral density and promote weight gain due to volume expansion and oedema, potentially causing or exacerbating heart failure and triggering ischemic cardiac events. 17, 18 Some insulin analogues are associated with a more physiological pattern of recovery; these drugs are more flexible to use and convenient to prescribe, and they allow greater freedom in diet while still providing improved quality of life. 6, 7, 25 Formulations eliminating the need for subcutaneous injections might correct some limitations of typical insulin therapy, thus improving glicemic control and increasing patient quality of life. 21 Some formulations that allow non-invasive administration of insulin are in the testing phase, including the inhalable insulin powders Exubera (Pfizer), Technosphere (MannKind), Aerdose (Aerogen), BAI (Kos), Alveair (Coremed),
and Bio-Air (BioSante). Therapy selection must take into account tolerability, non-glycaemic effects of antidiabetic agents, effects on associated comorbidities, and cost (Stolar et al., 2008 ).
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The limitations of conventional treatments that fail to preserve pancreatic beta cell function over time have resulted in a critical need to find new means to attain appropriate glycaemic control and avoid or delay the need for additional measures . 2 Thus, antidiabetic treatments seeking to preserve beta cell function and integrity and halt T2D progression are clearly needed. 8 More effective measures based on the disease aetiopathogenesis are necessary; these measures must control both fasting and postprandial glycaemia.
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A new approach to T2D treatment involves the use of therapies based on incretins such as dipeptydil peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists, which are GLP-1
analogues and bind to GLP-1 receptors on pancreatic beta cells to inactivate them. 2, 3 Both groups of drugs have proven safe and effective in reducing glycaemia and have yielded favourable effects regarding weight, lipid profile, and blood pressure. 9, 17, [26] [27] [28] Both are associated with insulin release and glucose-dependant glucagon suppression with consequent low hypoglycaemia risk. Experimental studies showed that these therapies prolong the survival, delay the dysfunction, and promote the regeneration of pancreatic beta cells and thus theoretically hold the potential to halt T2D progression. 3, 9, 28 Although these studies have demonstrated the therapeutic promise of DPP-4 and GLP-1 analogues, the high cost of these new agents and the lack of studies on their long-term safety must be considered. Nausea, headache, acute pancreatitis, upper airway infection, depression, severe hypoglycaemia, and skin allergic reactions have been reported with the use of these drugs. Some individuals also exhibit moderate reduction of glycated haemoglobin levels when compared to patients treated with insulin and older agents. Moreover, the development of carcinomas has been associated with the use of these agents in guinea pigs;
however, this finding has not been confirmed in humans. 18, 19, 28 In addition to the wide variety of pharmacological options for multidisciplinary treatment aimed at weight loss and glycaemic control, bariatric and metabolic surgical techniques can be included among the therapeutic approaches to T2D and insulin resistance.
These surgical interventions have been shown to provide long-term control of T2D.
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Surgical interventions in non-morbidly obese patients (BMI < 35)
Bariatric surgery can improve and eventually completely reverse obesity-associated comorbidities in 70% to 100% of patients, 31 thus increasing their life expectancy, 32 partially reversing hypothalamic dysfunction, and increasing the anti-inflammatory activity of the cerebrospinal fluid.
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Improved glycaemic control is observed months after adjustable gastric band surgery, and improvement is faster and more complete with ROUX-en-Y bypass. Both strategies can improve or even cure T2D, potentially through different mechanisms . 34 Vertical gastrectomy with or without contention ring and Roux-en-Y gastrojejunal bypassthought to be the gold standard surgical intervention in the treatment of morbid obesity -are known to achieve the goals of weight loss and control of comorbidities and to maintain these goals over time. 35 This control of comorbidities is usually attributed to body mass reduction;
however, a potentially glycaemia-controlling endocrine effect has been observed even before any significant weight loss. 36 After gastrojejunal bypass, levels of substances directly secreted by the bowel such as GLP-1 were found to be elevated in the peripheral blood; these substances can stimulate insulin production by pancreatic beta cells, facilitate insulin-mediated glucose transport into cells, and induce a feeling of satiety. 37 Roux-en-Y gastrojejunal bypass favours the stimulation of GLP-1-producing cells by foods arriving at the distal portions of the small intestine incompletely digested, as food transit is diverted to the proximal jejunum. 38 Jejunal bypass and other highly effective bariatric and metabolic surgical interventions deliver nutrient-rich chyme to the distal bowel earlier than normal. Its arrival directly to the ileum activates a negative feedback mechanism known as the "ileal brake", 39 which involves neuronal and endocrine mechanisms that influence stomach voiding, intestinal motility, and satiety.
As early as 1998, it was already thought that T2D might be an anterior bowel disease. 41 Currently, several clinical, physiological, biological, anthropological, epidemiological, anatomical, and evolutionary lines of evidences together with surgical results have confirmed that the proximal small intestine -whose size was appropriate for our ancestral environmentmight have become too large due to the modern industrialised diet. Consumers of a rich and modified modern diet developed a much larger anterior intestine (jejunum) than desired. A shorter jejunum prevent ingested food from being fully absorbed in the proximal portion of the intestine, allowing it to arrive at the distal intestine (ileum) almost in natura in order to stimulate L-type endocrine cells to produce substances such as GLP-1 that promote insulin production by the endocrine pancreas, facilitate glucidic metabolism in peripheral tissues, and induce satiety through selective hypothalamic inhibition. 42 The genesis of disruptions in glucose metabolism involves a multifaceted range of intimately intertwined factors. Of these factors, hormones are the most significant; of particular interest is GLP-1, which is produced by enteroendocrine L-cells of the small intestine, which are more densely concentrated at the terminal ileum. 32 GLP-1 is produced by tissuespecific post-translational processing of its precursors, namely, the peptide proglucagon, by pro-hormone convertase enzymes. 43 Post-translational modifications of the glucagon gene give rise to five different products in the bowel: glycentin, oxyntomodulin (OXM), intervening peptide-1 (IP-1), GLP-1, and GLP-2. 44 Proglucagon is processed in bowel L-cells by PC1/3 prohormone convertase. 43 GLP-1 secretion occurs in response to stimuli generated by nutrients with an incretin effect. 45 Incretins are hormones secreted into the blood circulation by the gastrointestinal tract in response to intake of certain nutrients. This results in increased insulin production and consequent glucose uptake. GLP-1 has well-defined functions, such as stimulation of glucose-dependent insulin secretion, upregulation of insulin gene transcription, induction of Langerhans islet beta cell neogenesis and proliferation, inhibition of beta cell apoptosis, increased phenotypic differentiation of beta cells, stimulation of somatostatin production, and reduction of glucagon production. 46, 47 Advances in neurogastroenterology have provided a better understanding of gastrointestinal physiology. Therefore, bariatric surgery intervention modalities evolved into the current mixed procedures that take into account neurohormonal and metabolic factors in addition to restriction and dysabsorption features. Thus, the term baroendocrine surgery is increasingly used, especially in the treatment of T2D. 38, 40 Currently, mixed (restrictive and dysabsorptive) bariatric surgery is the most efficacious treatment in patients with morbid obesity, resulting in significant improvement of associated comorbidities (Melissas, 2008) . 49 In studies of these interventions, enhanced GLP-1 release and improved glycaemic control have been observed even before significant weight loss, demonstrating that the control of diabetes might be related to hormonal effects secondary to the surgical technique performed.
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Isolated ileal interposition
In the early 1980s, enhanced GLP-1 release had already been shown to suffice for body weight control in obese rats treated with the interposition of a 5-or 10-cm terminal ileum fragment. 51 The effects of this surgery are illustrated in Figure 1 . (5) GLP-1 is an incretin and will also mediate insulin secretion and endocrine pancreas protection. 52 Another study in rats showed hypertrophy of transposed ileum together with increased serum GLP-1 levels. 53 In humans, GLP-1 increased after jejunoileal and biliopancreatic bypass in morbidly obese individuals. 54 Another study published in 1998
showed that patients exhibited high levels of GLP-1 even 20 years after jejunoileal bypass.
Together with a study published in 1999, these findings suggested that ileal interposition might be used as a treatment for T2D. 56 Fast and permanent improvements in glucose control were observed in patients immediately after bariatric surgery, and surgery eliminated the need for glycaemia-controlling drugs in most cases. 57, 58 The beneficial effects of bariatric surgery on glycaemic control also depend on the duration of disease 59 and the type of surgical intervention; interventions based solely on stomach restriction, such as adjustable gastric bands, proved to be less effective in improving T2D than procedures involving substantial amounts of intestinal bypass 55, 60, 61 or significant increases in digestive transit speed, such as vertical gastrectomy. 62, 63 Vertical gastrectomy is aimed mainly at achieving weight loss. It is a restrictive procedure due to the significant reduction in stomach reservoir capacity; moreover, it is considered a metabolic procedure, as it results in reduced circulating levels of the orexigenic hormone ghrelin, which is produced at the fundus and greater curvature of the stomach.
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The good long-term postoperative 64 glycaemic control achieved by vertical gastrectomy 63 might be due to the arrival of incompletely digested food at the distal ileum as a result of increased voiding speed after surgery, which in turn results in increased GLP-1 secretion by Lcells. 66 Ileal interposition has frequently been performed in obese and non-obese humans;
however, it is never performed in isolation. Promising results were recently obtained in humans using techniques combining vertical gastrectomy with the interposition of a segment of distal ileum in the trajectory of the proximal jejunum. [67] [68] [69] [70] [71] [72] This procedure can induce early satiety along with benefits to glucidic metabolism and cause short-and long-term weight loss.
In non-obese diabetic patients, vertical gastrectomy combined with ileal interposition effectively controlled T2D. [67] [68] [69] [70] [71] Analysis of the effects of vertical gastrectomy combined with ileal interposition on humans 6 and 18 months after the procedure demonstrated T2D remission in 80% of patients, who were freed from treatment with hypoglycaemic agents or diet. The remaining 20% of patients showed significant improvement despite the need to continue oral treatment (Tinoco, 2011) . 72 Despite these findings, however, there is a conceptual problem in proposing to perform vertical gastrectomy in non-obese diabetic patients: the metabolic benefits reported in the literature were probably due almost exclusively to ileal interposition rather than to the partial gastric restriction procedure (vertical gastrectomy).
The early postoperative improvement in glucose metabolism observed in obese and diabetic patients subjected to vertical gastrectomy alone 63 is most likely due to the increase in intestinal transit speed induced by intervention, 66 which favours quicker arrival of undigested food to the terminal ileum, where it stimulates L-cells to produce endogenous GLP-1. We conclude that in these non-obese patients with glucidic dysmetabolism, vertical gastrectomy improves glucose metabolism, but this effect is only due to the acceleration of gastrointestinal transit, which causes incompletely digested food to arrive at the terminal ileum, where it triggers GLP-1 production by L-cells. Other consequences of vertical gastrectomy, such as the restriction caused by making the gastric reservoir a small-calibre tube, and the anorexigenic effect caused by reducing levels of the orexigenic hormone ghrelin, 63 arise from the removal of the fundus and greater curvature of the stomach, where X/A-type neuroendocrine cells are more concentrated. However, vertical gastrectomy is a major surgical procedure that is not without significant complications, such as torpid evolution of fistulas and reflux esophagitis.
There is no reason to apply this procedure to non-obese diabetic patients, in whom isolated ileal interposition may be highly effective. Ileal interposition in rats involves placing a 10-to 20-cm segment of distal ileum with its nerves and vessels intact into the proximal jejunum, 73 resulting in significant hyperplasia, hypertrophy, and even full "jejunisation" of the transposed ileum. [74] [75] [76] [77] [78] Isolated ileal interposition proved efficacious in correcting dysmetabolism in several studies of experimental animals; 51, 79, 80 however, in the context of bariatric and metabolic surgery, this surgical modality involving only ileal interposition has not been assessed in humans.
Increased synthesis and release of GLP-1 can be attributed to increased stimulation of L-cells located in the interposed ileum segment in response to the presence of a greater amount of partially digested food, resulting in direct effects on glucidic metabolism (Patriti et al., 2007) . 81 Serum levels of GLP-1 increase in response to alimentary stimulation, resulting in a satiating effect on the central nervous system, 82 reduced fat absorption by the gastrointestinal tract, 83 and reduced gastric 84 and intestinal motility. 85 The most remarkable effects of GLP-1 are reduced peripheral insulin resistance, decreased apoptosis of pancreatic beta cells, increased differentiation of primitive pancreatic canaliculus cells into adult beta cells, and increased proliferation of beta cells. 86, 87 GLP-1 is the incretin hormone most associated with the antidiabetic effects of bariatric surgery. Stimulation of ileal L-cells to cleave proglucagon and release GLP-1 seems to be the most effective means of inducing the incretin effect in diabetic patients subjected to bariatric surgery. Several techniques might be applied to achieve this effect. All of these techniques are derived from the hindgut theory, which states that contact of partially digested food with the ileum corrects the deleterious effects of "empty ileum syndrome" caused by the lack of L-cell stimulation. 61, 81, 88 The results of the simple interposition of an ileum segment into the proximal segments of the small intestine are the strongest arguments supporting this hypothesis. A study of interposition in experimental animals subjected to a model of diet-induced obesity showed a significant increase in GLP-1 levels (Strader, 2006) . 52 Similarly, interposition of a 50-cm ileum segment distal to Treitz's angle in combination with vertical gastrectomy resulted in improved diabetes symptoms in a clinical trial.
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In addition to the "ileal brake" (a reaction that decreases proximal gastrointestinal transit motility and enterohormone 90, 91 production following ileal interposition surgery), ileal interposition also improved glucose tolerance in experimental, euglycaemic rats. 52, 92 These findings suggest that isolated ileal interposition might be a valid alternative for the treatment of diabetes. Due to the intestines' great capacity for adaptation, further research is necessary to justify ileal interposition as a surgical treatment for diabetes.
Specifically, studies addressing the ability of interposed ileum L-cells to continue to differentiate with a density similar to intact ileum; to fulfil their functions, including GLP-1 production, over time; and to contribute to the metabolic control of glucose levels will be necessary.
This project evaluated the effects of a surgical technique that interfered with the host's enteroendocrine function and investigated the histological changes in the mucosa of intestinal L cells in a segment of distal ileum that was interposed with the proximal jejunum in rats. 
UNIFESP-EPM).
The animals were transferred to the Biophysics Vivarium and housed in collective cages at a controlled room temperature of 23  2C with a relative humidity of 55  15% and a 12-hour light / dark cycle (6 am / 6 pm). The animals were transferred in installments to provide different aged groups for follow-up examinations in the animal housing facility.
Two 12-week old animals were separated for surgeries and randomly distributed into 2 groups: the Interposition Group (TG) was subjected to ileal interposition, and the Sham Group (SG) was subjected to sham operations.
A third group, the Control Group (CG), included animals that were not subjected to surgery.
All animals were followed until the 60 th postoperative day (PO), and they were sacrificed according to the organogram (Figure 2 ). 
Experimental procedures
Diet
The animals received a normocaloric (4.5 Kcal/g) and normolipidic diet that contained 10% fat, 20% protein and 70% carbohydrates ad libitum (Nuvilab CR-1, Nuvital Nutrientes SA) throughout the study.
Anesthesia
A dissociative general anesthetic, 20 mg/kg Zoletil® 50 (tiletamine + zolazepam) and 0.025 mg/kg fentanyl, was simultaneously injected intramuscularly prior to surgical interventions. 93 The animals maintained spontaneous ventilation throughout the procedures, and the anesthetic plane was controlled using periodic evaluations of auricular and interdigital reflexes, which should be absent, every 45 minutes. Anesthesia was complemented with 1/3 of the initial anesthetic dose when these reflexes reappeared. 
Surgical procedures
Two rats were separated and randomly distributed into the TG or SG. Only water was provided to the animals for 6 hours prior to surgical procedures.
The anesthetized animals were placed in a dorsal decubitus position on the operating table, and their paws and tails were bound with tape. The skin in the abdominal region was treated with chlorhexidine in an aqueous vehicle. The fur was not shaved.
The abdominal region was covered with a fenestrated sterile surgical drape (Figure 3) , and a medial longitudinal surgical incision approximately 5 cm in length was made in the abdominal wall using a #15 disposable scalpel blade (Figure 4 ). The cecum was initially identified and exposed ( Figure 5 ) with the terminal ileum. The small intestine was sectioned perpendicularly 4 cm and 5 cm from the ileocecal transition in both surgical intervention groups to remove a 1-cm segment of the ileum for histological analysis. The ileum was sectioned perpendicularly 5 cm and 15 cm from the ileocecal transition in the TG to separate a 10-cm segment ( Figure 6A ). This segment was wrapped in gauze that was moistened with a warm solution of 0.9% sodium chloride. The continuity of the digestive tract was restored by anastomosis of the remaining ileal segments. The jejunum was sectioned 5 cm from the duodenojejunal transition. The previously separated segment of the distal ileum was interposed with the sectioned segments of the jejunum in an isoperistaltic position ( Figure   6B ). The intestine was sectioned perpendicularly 5 cm and 15 cm from the ileocecal transition and 5 cm from the duodenojejunal transition in the SG. The digestive tract was immediately reconstructed using termino-terminal anastomosis. A 1-cm segment was removed from the distal ileum for histological and molecular biology analyses. All intestinal anastomoses were termino-terminal using 6 separate 7-0 polypropylene sutures that were premounted in a cylindrical needle (Figure 7 ). Abdominal wall closure was performed using a continuous suture en bloc of the parietal peritoneum, muscular layer and aponeurosis using a 4-0 polyglactin suture that was premounted in a cylindrical needle. Continuous suture was performed on the skin using a 4-0 polyglactin that was premounted in a cylindrical needle using reverse stitches.
Hydration was performed at the end of the surgery using a subcutaneous injection of a 0.5% saline solution in the dorsum of the animals at a dose of 10 ml/kg body weight.
Postoperative evolution
The animals were observed until they fully recovered from anesthesia. The animals were subsequently placed in individual cages and maintained in the shelter room of the Biophysics Vivarium under the same preoperative environmental conditions. Diet and water ad libitum were reintroduced after recovery from anesthesia.
Operated animals were monitored and assessed until the 60 th postoperative (PO) day, which corresponded to 8 PO weeks and 20 weeks of age. These assessments investigated the long-term effects of surgery because 60 days in a rat correlates to approximately 3 years in humans. The animals in the CG were also euthanized at 20 weeks of age.
Euthanasia
Euthanasia was performed by decapitation as directed by the Brazilian College of Animal Experimentation (COBEA) on the 60 th PO day (8 PO weeks and 20 weeks of age) in the TG and SG and at 16 weeks of age in the CG.
Histology -Optical microscopy and immunohistochemistry
The following tissues were collected during surgery for histological analysis: a) Segment of the proximal jejunum -Segment JE 1 (jejunum, moment 1); b) Segment of the distal ileum -Segment IL 1 (ileum, moment 1).
The following tissues were collected for histological analysis after euthanasia: Histological sections for light microscopy were fixed for 12 to 24 hours in 10% buffered formaldehyde with monobasic sodium phosphate, dibasic sodium phosphate and NaCl in a volume that was 20 times greater than the volume of the tissue. Five 1-hour baths were performed in 100% ethyl alcohol for dehydration followed by 2 1-hour baths in xylene to promote tissue diaphanousness. Histological sections were processed for liquid paraffin embedding at 58°C in 2 1-hour baths.
The histological sections were sent to the inclusion center for the preparation of the block. The inclusion center opened the cassettes, and the material was placed in a metal mold.
Additional paraffin and ice were added, and the slides were subjected to histological sectioning in a rotary microtome at a thickness of 3 m. The slices were placed on silanized slides for immunohistochemistry. The slides were placed in an oven for 20 minutes for tissue section adhesion.
The slides were crafted and stained using an anti-GLP-1 polyclonal antibody (Code AB26278 from Abcam, specific for immunohistochemical analysis).
The histological sections were fixed in 10% buffered formaldehyde for 24 hours and processed for paraffin embedding. The sections were sliced using a Minot microtome at a thickness of 5 mm and placed on slides that were previously treated with 5% silane. The slides containing the sections were subjected to the following protocol: 
Capturing, editing, image selection, cell counting method and the technique for measuring crypt area
Immunostaining was assessed using image representation through a computer system that included a light microscope (Carl Zeiss) adapted to a high-resolution camera (Carl Zeiss
Axiocam MRC) and a color video monitor (Samsung®). Histological sections were assessed at 400X, and photomicrographs were taken sequentially around the intestinal perimeter using 
Study parameters
The following data were used as study parameters: A 5% level of significance was used for all conclusions that were obtained through the inferential analyses.
Before ileal interposition
The following data were observed prior to surgical intervention: The TG demonstrated an L cells/area of crypt ratio that was similar to the SG for both intestinal segments of the jejunum and ileum prior to ileal interposition (Tables 1 and 2 ;
After ileal interposition
Figures 15 and 16). This relationship was expected because all of the animals were in the same sample with no prior intervention or procedure. These animals served as comparisons for the after ileal interposition time point to avoid the possibility that this ratio differed significantly and independently from the proposed surgery between groups.
Ileal interposition yielded the following results. The L cells/area of the crypt ratio in the intestinal segment of the jejunum remained similar in the CG, SG and TG with no significant differences (Table 3 and Figure 15 ). The L cells/area of the crypt ratio in the intestinal segment of the ileum remained similar in the CG, SG and TG with no significant differences (Table 4 and Figure 16 ). The L cells/area of the crypt ratio in the intestinal segment that corresponded to the interposed ileum and the intestinal segment of the interposed ileum were similar in the CG, SG and TG with no significant differences (Table 5 and Figure 17) .
A comparison of the L cells/area of the crypt ratio in intestinal segments of the jejunum and ileum with the interposed segment in the SG prior to and after surgical intervention revealed that this ratio remained similar with no significant differences. However, the L cells/area of the crypt ratio was increased in the distal segment of the ileum after surgical intervention ( Table 6 ).
The L cells/area of the crypt ratio in intestinal segments of the jejunum, ileum and the interposed ileum in the TG remained similar prior to and after surgical intervention with no significant differences ( Table 7) .
The individual average profiles of the L cells/area of the crypt ratios were maintained over time in the intestinal segments of the jejunum and the simulated intestinal segment of the ileum to the interposed segment and the interposed ileal segment in the TG and SG, respectively (Figures 15 and 16) . However, the average profile of the L cells/area of the crypt ratio in the intestinal segment of the ileum was increased in the SG.
No significant alterations in the L cells/area of the crypt ratio were noted in the intestinal segment at any time after ileal interposition, except for the ileal segment after surgical intervention in the SG.
The present study demonstrated that intestinal segments maintained their characteristics after a surgical procedure in which a segment of distal ileum was interposed to a region of the proximal jejunum. The segment of interposed ileum maintained its histological, and likely endocrine, characteristics with belatedly active L cells as well as the L cells/area of the crypt ratio in the interposed and other intestinal segments prior to and after ileal interposition.
Therefore, the interposition of a distal ileum segment to a region of the proximal jejunum or surgical procedures that shorten the path of ingested food through the digestive tract allow for a greater contact of the L cells of the distal small intestines with nutrients, which stimulates the early release of incretin hormones. 85, 88, 81, 94, 95, 91 This result may explain the improvements in the clinical and laboratorial conditions of patients with metabolic syndrome who undergo these procedures.
Moreover, bariatric and metabolic surgical techniques are viable and feasible for the treatment of metabolic diseases (mainly diabetes [96] [97] [98] ) due to their reduced technical complexity, a reduction in the isolated and resected segments, fewer complications than other bariatric procedures 99 and lower costs. However, the most appropriate surgical techniques for each patient should be determined individually because the expected and obtained results depend on the technique that is used. 
CONCLUSION
No structural and histological changes in intestinal L cells in the interposed intestinal segment and other intestinal segments were noted after ileal interposition surgery in normal rats. Therefore, the endocrine characteristics of these cells were likely maintained, which justifies the use of bariatric and metabolic surgical techniques for the treatment of metabolic diseases, especially diabetes.
